Merck & Co: planning to reap sweet rewards in diabetes (Pharmaceutical Business Review)
Merck & Co has revealed plans to file for FDA approval of MK-0431A in 2006, potentially enabling it to overtake Novartis in the race to commercialize the first DPP-4 inhibitor. The news is also of particular significance to Mercks diabetes pipeline following its failure to successfully launch a drug in the dual PPAR class.

09 June 2006 (PharmiWeb)
April 25, 2006 | Minneapolis, MN With the number of Class I recalls and warnings on the increase within the last few years, the FDA is taking a closer look at the medical device market and the need for overall improvements on their regulatory compliance and quality assurance.

FDA orders unapproved antihistamine medicines off market (KARE 11 Minneapolis-St. Paul)
Manufacturers of cold, cough and allergy medicines that contain the antihistamine carbinoxamine and have not been approved have been given 30 to 90